Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Study: Brain's 'autopilot' network may aid in early diagnosis of Alzheimer's disease

Study: Brain's 'autopilot' network may aid in early diagnosis of Alzheimer's disease

MicroRNA-29 molecule makes brain cells resistant to programmed cell death

MicroRNA-29 molecule makes brain cells resistant to programmed cell death

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Safely Home program helps police find and return individuals with dementia to their homes

Safely Home program helps police find and return individuals with dementia to their homes

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

New guideline recommends plasmapheresis usage to treat people with severe relapses in MS, neuropathies

Research: Adults with ADHD are more likely to develop degenerative dementia

Research: Adults with ADHD are more likely to develop degenerative dementia

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Johns Hopkins' online tool helps seniors assess risk for dementia

Johns Hopkins' online tool helps seniors assess risk for dementia

Better understanding of rotational motion in living cells may help researchers study causes of deadly diseases

Better understanding of rotational motion in living cells may help researchers study causes of deadly diseases

Video submissions invited for the 2011 Neuro Film Festival competition

Video submissions invited for the 2011 Neuro Film Festival competition

Brain cell destroying genetic mechanism responsible for development of AD

Brain cell destroying genetic mechanism responsible for development of AD

7,8-Dihydroxyflavone holds potential for treatment of fear based disorders

7,8-Dihydroxyflavone holds potential for treatment of fear based disorders

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

UCLA imaging system could help reveal 'miscommunications' in autism, schizophrenia

UCLA imaging system could help reveal 'miscommunications' in autism, schizophrenia

Aβ, tau and Fyn protein interactions may lead to brain dysfunction and AD

Aβ, tau and Fyn protein interactions may lead to brain dysfunction and AD

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

Lipoprotein receptor LRP1 also regulates food intake and energy balance in central nervous system: Study

Lipoprotein receptor LRP1 also regulates food intake and energy balance in central nervous system: Study

Study reveals underlying causes for degeneration of synapses in Alzheimer's Disease

Study reveals underlying causes for degeneration of synapses in Alzheimer's Disease

Mithridion secures commitments of $1.25 million in new funding

Mithridion secures commitments of $1.25 million in new funding

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.